MicroRNAs in cancer

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 287-314

  Di Leva, Gianpiero ^a   Garofalo, Michela ^a   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer; MicroRNAs; MiRs; Noncoding RNAs

Indexed keywords

MESSENGER RNA; MICRORNA;

ANIMAL; APOPTOSIS; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; HUMANS; MICRORNAS; NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84907485172     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104715     Document Type: Article

References (149)

1. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-54
2. Reinhart BJ, Slack FJ, BassonM, Pasquinelli AE, Bettinger JC, et al. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901-6
3. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. 2001. Identification of novel genes coding for small expressed RNAs. Science 294:853-58
4. Lau NC, Lim LP, Weinstein EG, Bartel DP. 2001. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294:858-62
5. Lee RC, Ambros V. 2001. An extensive class of small RNAs in Caenorhabditis elegans. Science 294:862-64
6. Kozomara A, Griffiths-Jones S. 2011. miRBase: integratingmicroRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:D152-57
7. Tanzer A, Stadler PF. 2004. Molecular evolution of a microRNA cluster. J. Mol. Biol. 339:327-35
8. LeeY, Kim M, Han J, YeomKH, Lee S, et al. 2004. MicroRNA genes are transcribed byRNApolymerase II. EMBO J. 23:4051-60
9. Cai X, Hagedorn CH, Cullen BR. 2004. HumanmicroRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10:1957-66
10. Borchert GM, LanierW, Davidson BL. 2006. RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 13:1097-101
11. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-97
12. Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92-105
13. Kim VN, Han J, Siomi MC. 2009. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10:126-39
14. Kim VN. 2004. MicroRNA precursors in motion: Exportin-5 mediates their nuclear export. Trends Cell Biol. 14:156-59
15. Kim VN. 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6:376-85
16. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. 2002. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21:4663-70
17. Han J, Lee Y, Yeom KH, Kim YK, Jin H, et al. 2004. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18:3016-27
18. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. 2006. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res. 34:4622-29
19. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, et al. 2001. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293:834-38
20. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, et al. 2001. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15:2654-59
21. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. 2005. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436:740-44
22. Lee Y, Hur I, Park SY, Kim YK, Suh MR, et al. 2006. The role of PACT in the RNA silencing pathway. EMBO J. 25:522-32
23. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, et al. 2003. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208
24. Khvorova A, Reynolds A, Jayasena SD. 2003. Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-16
25. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-33
26. Djuranovic S, Nahvi A, Green R. 2011. A parsimonious model for gene regulation by miRNAs. Science 331:550-53
27. John B, Enright AJ, Aravin A, Tuschl T, Sander C, et al. 2004. Human microRNA targets. PLoS Biol. 2:e363
28. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. 2005. Combinatorial microRNA target predictions. Nat. Genet. 37:495-500
29. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115:787-98
30. Maragkakis M, Vergoulis T, Alexiou P, Reczko M, Plomaritou K, et al. 2011. DIANA-microT web server upgrade supports fly and worm miRNA target prediction and bibliographic miRNA to disease association. Nucleic Acids Res. 39:W145-48
31. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. 2007. The role of site accessibility in microRNA target recognition. Nat. Genet. 39:1278-84
32. Loher P, Rigoutsos I. 2012. Interactive exploration of RNA22 microRNA target predictions. Bioinformatics 28:3322-23
33. Calin GA, DumitruCD, ShimizuM, BichiR, Zupo S, et al. 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99:15524-29
34. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6:857-66
35. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-38
36. Lambertz I, Nittner D, Mestdagh P, Denecker G, Vandesompele J, et al. 2010. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ. 17:633-41
37. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, et al. 2009. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23:2700-4
38. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103:2257-61
39. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, et al. 2006. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E?-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA 103:7024-29
40. Medina PP, NoldeM, Slack FJ. 2010. OncomiR addiction in an in vivomodel ofmicroRNA-21-induced pre-B-cell lymphoma. Nature 467:86-90
41. Kota J, Chivukula RR, ODonnell KA, Wentzel EA, Montgomery CL, et al. 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-17
42. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, et al. 2011. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 10:1470-80
43. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, et al. 2010. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29:1580-87
44. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, et al. 2005. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. USA 102:18081-86
45. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. 2012. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr. Mol. Med. 12:27-33
46. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. 2008. Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. Science 320:1643-47
47. Mayr C, Bartel DP. 2009. Widespread shortening of 3′ UTRsby alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138:673-84
48. Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103:12481-86
49. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-κB, Lin28, let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706
50. Seitz H. 2009. Redefining microRNA targets. Curr. Biol. 19:870-73
51. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, et al. 2010. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033-38
52. Cesana M, Cacchiarelli D, Legnini I, Santini T, SthandierO, et al. 2011. A long noncodingRNAcontrols muscle differentiation by functioning as a competing endogenous RNA. Cell 147:358-69
53. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, et al. 2011. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95
54. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, et al. 2011. An extensivemicroRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147:370-81
55. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, et al. 2011. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147:344-57
56. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, et al. 2011. MicroRNAs in body fluids-The mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8:467-77
57. Boeri M, Verri C, Conte D, Roz L, Modena P, et al. 2011. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. USA 108:3713-18
58. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. 2011. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 108:5003-8
59. FabbriM, Paone A, Calore F, Galli R, Gaudio E, et al. 2012. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 109:12278-79
60. Ventura A, Jacks T. 2009. MicroRNAs and cancer: Short RNAs go a long way. Cell 136:586-91
61. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, et al. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9:405-14
62. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. 2005. A microRNA polycistron as a potential human oncogene. Nature 435:828-33
63. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, et al. 2012. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 56:1025-33
64. Klein U, Lia M, Crespo M, Siegel R, Shen Q, et al. 2010. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28-40
65. Hsu SH, Wang B, Kota J, Yu J, Costinean S, et al. 2012. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig. 122:2871-83
66. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, et al. 2012. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Investig. 122:2884-97
67. Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, et al. 2012. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet. 8:e1002797
68. Calin GA, Ferracin M, Cimmino A, DiLeva G, Shimizu M, et al. 2005. AmicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353:1793-801
69. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. 2004. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39:167-69
70. Kluiver J, Poppema S, de Jong D, BlokzijlT, Harms G, et al. 2005. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 207:243-49
71. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, et al. 2008. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183-89
72. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065-70
73. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 101:2999-3004
74. Mu P, Han YC, Betel D, Yao E, Squatrito M, et al. 2009. Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 23:2806-11
75. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, et al. 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23:2839-49
76. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, et al. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17∼92 family of miRNA clusters. Cell 132:875-86
77. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, et al. 2010. Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenicPTEN-targeting intron that cooperateswith its host geneMCM7 in transformation. Sci. Signal. 3:ra29
78. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, et al. 2010. Modulation of K-Rasdependent lung tumorigenesis by microRNA-21. Cancer Cell 18:282-93
79. Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, et al. 2007. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109:5079-86
80. LiaM, Carette A, Tang H, Shen Q, Mo T, et al. 2012. Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood 119:2981-90
81. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, et al. 2008. LNA-mediated microRNA silencing in non-human primates. Nature 452:896-99
82. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-34
83. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. 2008. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359:2641-50
84. Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, YangW, et al. 2012. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N. Engl. J. Med. 366:234-42
85. Esteller M. 2008. Epigenetics in cancer. N. Engl. J. Med. 358:1148-59
86. Lopez-Serra P, Esteller M. 2012. DNA methylation-Associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31:1609-22
87. Fabbri M, Calore F, Paone A, Galli R, Calin GA. 2013. Epigenetic regulation of miRNAs in cancer. Adv. Exp. Med. Biol. 754:137-48
88. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al. 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-43
89. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67:1424-29
90. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 104:15805-10
91. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, et al. 2009. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113:6411-18
92. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, et al. 2008. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695-99
93. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, et al. 2010. Loss of miR-200 inhibition of Suz12 leads to Polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell 39:761-72
94. ODonnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. 2005. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839-43
95. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, et al. 2009. The estrogen receptor-α- induced microRNA signature regulates itself and its transcriptional response. Proc. Natl. Acad. Sci. USA 106:15732-37
96. Bast RC Jr, Hennessy B, Mills GB. 2009. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 9:415-28
97. Corney DC, Flesken-Nikitin A, Godwin AK, WangW, Nikitin AY. 2007. MicroRNA-34b and microRNA- 34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67:8433-38
98. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, et al. 2009. Modulation of microRNA processing by p53. Nature 460:529-33
99. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, et al. 2010. A genetic defect in Exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18:303-15
100. Melo SA, Ropero S, Moutinho C, Aaltonen LA, YamamotoH, et al. 2009. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet. 41:365-70
101. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, et al. 2006. Extensive posttranscriptional regulation of microRNAs and its implications for cancer. Genes Dev. 20:2202-7
102. Hagan JP, Piskounova E, Gregory RI. 2009. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat. Struct. Mol. Biol. 16:1021-25
103. Wu L, Belasco JG. 2005. Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol. Cell. Biol. 25:9198-208
104. Thornton JE, Gregory RI. 2012. How does Lin28 let-7 control development and disease? Trends Cell Biol. 22:474-82
105. Cimmino A, Calin GA, FabbriM, Iorio MV, Ferracin M, et al. 2006. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102:13944-49
106. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. 2008. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68:6162-70
107. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, et al. 2009. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 26:6669-80
108. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, et al. 2011. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 30:4231-42
109. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, et al. 2012. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 72:5945-55
110. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, et al. 2004. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64:3753-56
111. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635-47
112. Guan H, Zhang P, Liu C, Zhang J, Huang Z, et al. 2011. Characterization and functional analysis of the human microRNA let-7a2 promoter in lung cancer A549 cell lines. Mol. Biol. Rep. 38:5327-34
113. Hu X, Guo J, Zheng L, Li C, Zheng TM, et al. 2013. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol. Cancer Res. 11:240-50
114. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. 2007. p53-Mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17:1298-307
115. Wang LG, Ni Y, Su BH, Mu XR, ShenHC, et al. 2013. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int. J. Oncol. 42:957-62
116. Mongroo PS, Rustgi AK. 2010. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol. Ther. 10:219-22
117. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10:593-601
118. Korpal M, Lee ES, Hu G, Kang Y. 2008. ThemiR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283:14910-14
119. Park SM, GaurAB, LengyelE, Peter ME. 2008. ThemiR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894-907
120. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, et al. 2008. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68:7846-54
121. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, et al. 2010. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 5:e8697
122. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, et al. 2009. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci. Signal. 2:ra62
123. Visvader JE, Lindeman GJ. 2012. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10:717-28
124. Polytarchou C, Iliopoulos D, Struhl K. 2012. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc. Natl. Acad. Sci. USA 109:14470-75
125. Eis PS, Tam W, Sun L, Chadburn A, Li Z, et al. 2005. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 102:2627-32
126. van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, et al. 2004. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 39:167-69
127. OConnell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, et al. 2008. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp.Med. 205:585-94
128. Wang X, Tang S, Le SY, Lu R, Rader JS, et al. 2008. Aberrant expression of oncogenic and tumorsuppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3:e2557
129. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, et al. 2007. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120:1046-54
130. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. 2008. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93:1600-8
131. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-98
132. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, et al. 2004. Identification and characterization of a novel C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 64:3087-95
133. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, et al. 2005. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65:9628-32
134. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, et al. 2008. E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13:272-86
135. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, et al. 2008. miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27:5651-61
136. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, et al. 2010. MicroRNA cluster 221-222 and estrogen receptor αinteractions in breast cancer. J. Natl. Cancer Inst. 102:706-21
137. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, et al. 2006. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr.-Relat. Cancer 13:497-508
138. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, et al. 2008. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 68:2745-54
139. Stinson S, LacknerMR, Adai AT, YuN, Kim HJ, et al. 2011. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci. Signal. 4:ra41
140. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, et al. 2007. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26:3699-708
141. Garofalo M, Romano G, DiLeva G, Nuovo G, Jeon YJ, et al. 2011. EGFR and MET receptor tyrosine kinase-Altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18:74-82
142. Krutzfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, et al. 2007. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 35:2885-92
143. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. 2005. Silencing of microRNAs in vivo with "antagomirs." Nature 438:685-89
144. Levin AA. 1999. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489:69-84
145. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. 2006. miR122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3:87-98
146. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201
147. Bader AG, Brown D, Winkler M. 2010. The promise of microRNA replacement therapy. Cancer Res. 70:7027-30
148. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-41
149. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. 2010. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70:5923-30